NCT07054255View on ClinicalTrials.gov

Bioequivalence Study of Ranolazine Extended-release Tablets in Healthy Chinese Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

September 6, 2020

Primary Completion Date

November 9, 2020

Study Completion Date

December 21, 2020

Conditions
Healthy
Interventions
DRUG

Test formulation (Ranolazine extended-release tablets)

A single oral dose of 500 mg, taken with 240mL of water

DRUG

Reference formulation (Ranolazine extended-release tablets)

A single oral dose of 500 mg, taken with 240mL of water

Trial Locations (1)

Unknown

Zhongda Hospital, Southeast University, Nanjing

All Listed Sponsors
lead

Haisco Pharmaceutical Group Co., Ltd.

INDUSTRY

NCT07054255 - Bioequivalence Study of Ranolazine Extended-release Tablets in Healthy Chinese Subjects | Biotech Hunter | Biotech Hunter